Clinical implications of renin–angiotensin system inhibitors for development and progression of non-alcoholic fatty liver disease
Abstract Recently, there has been an increasing interest in the therapeutic efficacy of RAS inhibitors (RASi) in patients with non-alcoholic fatty liver disease (NAFLD) because they may reduce oxidative stress, inflammatory markers, and enhanced fibrosis. An objective of this study was to investigat...
Main Authors: | Kwang Min Kim, Ji-Hye Roh, Sangjin Lee, Jeong-Hyun Yoon |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2021-02-01
|
Series: | Scientific Reports |
Online Access: | https://doi.org/10.1038/s41598-021-81959-1 |
Similar Items
-
The impact of Renin-Angiotensin System Inhibitors on bone fracture risk: a nationwide nested case-control study
by: Kwang Min Kim, et al.
Published: (2024-01-01) -
Renin-Angiotensin System Inhibitors, Type 2 Diabetes and Fibrosis Progression: An Observational Study in Patients with Nonalcoholic Fatty Liver Disease.
by: Serena Pelusi, et al.
Published: (2016-01-01) -
Therapeutic effect of renin angiotensin system inhibitors on liver fibrosis
by: Qianqian Zhu, et al.
Published: (2016-02-01) -
Combination renin-angiotensin system blockade with the renin inhibitor aliskiren in hypertension
by: Timothy WR Doulton, et al.
Published: (2009-12-01) -
Captopril, a Renin–Angiotensin System Inhibitor, Attenuates Tumour Progression in the Regenerating Liver Following Partial Hepatectomy
by: Georgina E. Riddiough, et al.
Published: (2022-05-01)